These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

178 related items for PubMed ID: 9010691

  • 21. Beneficial effects of intravenous administration of lipo-prostaglandin E1 on the ischemic gastric tube in pigs.
    Tobari S, Ikeda Y, Takami H.
    J Surg Res; 2005 Nov; 129(1):79-84. PubMed ID: 16087193
    [Abstract] [Full Text] [Related]

  • 22. Parenteral therapy with lipo-ecraprost, a lipid-based formulation of a PGE1 analog, does not alter six-month outcomes in patients with critical leg ischemia.
    Brass EP, Anthony R, Dormandy J, Hiatt WR, Jiao J, Nakanishi A, McNamara T, Nehler M, Circulase investigators.
    J Vasc Surg; 2006 Apr; 43(4):752-9. PubMed ID: 16616232
    [Abstract] [Full Text] [Related]

  • 23. A multicenter double blind controlled study of lipo-PGE1, PGE1 incorporated in lipid microspheres, in peripheral vascular disease secondary to connective tissue disorders.
    Mizushima Y, Shiokawa Y, Homma M, Kashiwazaki S, Ichikawa Y, Hashimoto H, Sakuma A.
    J Rheumatol; 1987 Feb; 14(1):97-101. PubMed ID: 3553591
    [Abstract] [Full Text] [Related]

  • 24. Effects of intravenous lipoprostaglandin E1 on neurogenic intermittent claudication.
    Murakami M, Takahashi K, Sekikawa T, Yasuhara K, Yamagata M, Moriya H.
    J Spinal Disord; 1997 Dec; 10(6):499-504. PubMed ID: 9438815
    [Abstract] [Full Text] [Related]

  • 25. Midterm results of prostaglandin E1 treatment in patients with lumbar spinal canal stenosis accompanied by intermittent claudication.
    Nakanishi K, Tanaka M, Misawa H, Takigawa T, Ozaki T.
    Spine (Phila Pa 1976); 2008 Jun 01; 33(13):1465-9. PubMed ID: 18520942
    [Abstract] [Full Text] [Related]

  • 26. Ocular and orbital blood flow velocity in patients with peripheral vascular disease and diabetes treated with intravenous prostaglandin E1.
    Steigerwalt RD, Belcaro GV, Christopoulos V, Incandela L, Cesarone MR, De Sanctis MT.
    J Ocul Pharmacol Ther; 2001 Dec 01; 17(6):529-35. PubMed ID: 11777176
    [Abstract] [Full Text] [Related]

  • 27. Protective effect of lipid microspheres 1 on myocardial injury following elective percutaneous coronary intervention in patients with angina pectoris: a pilot study.
    Chu-fan L, Xing W, Xun H, Gui-fu W, Cheng-heng H, Zhi-min D.
    J Cardiovasc Med (Hagerstown); 2011 Nov 01; 12(11):790-4. PubMed ID: 21934521
    [Abstract] [Full Text] [Related]

  • 28. PGE(1) treatment of severe intermittent claudication (short-term versus long-term, associated with exercise)--efficacy and costs in a 20-week, randomized trial.
    Belcaro G, Nicolaides AN, Agus G, Cesarone MR, Geroulakos G, Pellegrini L, De Sanctis MT, Incandela L, Ricci A, Mondani P, De Angelis R, Ippolito E, Barsotti A, Vasdekis S, Ledda A, Christopoulos D, Errichi BM, Helmis H, Cornelli U, Ramaswami G, Dugall M, Bucci M, Martines G, Ferrari PG, Corsi M, Di Francescantonio D.
    Angiology; 2000 Aug 01; 51(8 Pt 2):S15-26. PubMed ID: 10959507
    [Abstract] [Full Text] [Related]

  • 29. Prostaglandin E1 in peripheral vascular disease: a PET study of muscular blood flow.
    Schellong SM, Burchert W, Böger RM, Creutzig A, Hundeshagen H, Alexander K.
    Scand J Clin Lab Invest; 1998 Apr 01; 58(2):109-17. PubMed ID: 9587162
    [Abstract] [Full Text] [Related]

  • 30. Effects of prostaglandin E1 infusion on limb hemodynamics and vasodilatory response in patients with arteriosclerosis obliterans.
    Makita S, Nakamura M, Ohhira A, Itoh S, Hiramori K.
    Cardiovasc Drugs Ther; 1997 Jul 01; 11(3):441-8. PubMed ID: 9310272
    [Abstract] [Full Text] [Related]

  • 31. The role of age in determining the effects of lipo-PGE1 infusion on immediate arterial maximal flow velocity in patients with diabetes undergoing free flap surgery for lower extremity reconstruction: A prospective observational study.
    Park JY, Jin SJ, Suh HP, Lee SA, Cho C, Yu J, Hwang JH, Hong JP, Kim YK.
    J Plast Reconstr Aesthet Surg; 2020 May 01; 73(5):885-892. PubMed ID: 31924534
    [Abstract] [Full Text] [Related]

  • 32. Neutrophil function in peripheral arterial occlusive disease: the effects of prostaglandin E1.
    Weiss T, Eckstein H, Weiss C, Diehm C.
    Vasc Med; 1998 May 01; 3(3):171-5. PubMed ID: 9892509
    [Abstract] [Full Text] [Related]

  • 33. Specific augmentation of plantar skin blood flow by lipo-PGE1 assessed in tetrodotoxin- and N(G)-nitro-L-arginine-treated rats.
    Chino D, Akimaru S, Kataha K, Ishii K, Nakayama K.
    J Cardiovasc Pharmacol; 2000 Apr 01; 35(4):630-7. PubMed ID: 10774795
    [Abstract] [Full Text] [Related]

  • 34. Prostaglandin E1 increases the blood flow rate of saphenous vein grafts in patients undergoing off-pump coronary artery bypass grafting.
    Zhao L, Lu J, Wang C, Zhao W, Qing E, Ma J.
    J Cardiothorac Vasc Anesth; 2013 Dec 01; 27(6):1208-11. PubMed ID: 24090805
    [Abstract] [Full Text] [Related]

  • 35. Effects of liposomal prostaglandin E1 on periprocedural myocardial injury in patients with unstable angina undergoing an elective percutaneous coronary intervention.
    Fan Y, Jiang Y, Fu X, Cai J, Wang Y, Li W, Gu X, Xing K, Bai S, Bi X.
    Coron Artery Dis; 2015 Dec 01; 26(8):671-7. PubMed ID: 26267747
    [Abstract] [Full Text] [Related]

  • 36. Prostaglandin E1 incorporated in lipid microspheres in the treatment of peripheral vascular diseases and diabetic neuropathy.
    Hoshi K, Mizushima Y, Kiyokawa S, Yanagawa A.
    Drugs Exp Clin Res; 1986 Dec 01; 12(8):681-5. PubMed ID: 3757764
    [Abstract] [Full Text] [Related]

  • 37. Randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of AS-013, a prostaglandin E1 prodrug, in patients with intermittent claudication.
    Belch JJ, Bell PR, Creissen D, Dormandy JA, Kester RC, McCollum RD, Mizushima Y, Ruckley CV, Scurr JH, Wolfe JH.
    Circulation; 1997 May 06; 95(9):2298-302. PubMed ID: 9142008
    [Abstract] [Full Text] [Related]

  • 38. [Intramuscular injections of PGE1 in patients with severe claudication].
    Corsi M, Laurora G, Cesarone MR.
    Minerva Cardioangiol; 1998 Oct 06; 46(10 Suppl 1):59-63. PubMed ID: 10658447
    [Abstract] [Full Text] [Related]

  • 39. Echocardiographic evaluation of the ductal morphology in patients with refractoriness to lipo-prostaglandin E1 therapy.
    Takeda N, Hiraishi S, Misawa H, Agata Y, Horiguchi Y, Fujino N, Hirota H, Kawamura S, Ogawa N.
    Pediatr Int; 2000 Apr 06; 42(2):134-8. PubMed ID: 10804727
    [Abstract] [Full Text] [Related]

  • 40. Therapeutic efficacy of intravenously applied prostaglandin E1.
    Scheffler P, de la Hamette D, Leipnitz G.
    Vasa Suppl; 1989 Apr 06; 28():19-25. PubMed ID: 2609240
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.